Pack Size Serving 30 Capsules
In laboratory settings, GHK-CU serves as a model compound for studying peptide-metal interactions, copper ion coordination chemistry, and related biochemical pathways
A larger clinical trial randomly assigned more than 500 patients with type 2 diabetes and symptomatic peripheral neuropathy to one of the following treatments: (i) 600 mg/day of intravenous lipoic acid for three weeks followed by 1,800 mg/day of oral lipoic acid for six months, (ii) 600 mg/day of intravenous lipoic acid for three weeks followed by oral placebo for six months, or (iii) intravenous placebo for three weeks followed by oral placebo for six months (76)
Full texts of included papers written entirely in English with available abstracts and at least one of the following characteristics were considered: clinical and/or preclinical studies on the role of GSH in cancer patients, with particular regard to antioxidants effects, diet, toxicities, and pharmacological processes, including pharmacokinetic aspects and risk of interactions
[2]Current Patent Assignee: NEW SOUTH INNOVATIONS - US2006/166208, 2006, A1 Location in patent: Page/Page column 16
Exosome-like nanovectors for drug delivery in cancer
